Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Yu

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Brain and Behavior|October 1, 2016
Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosisRuth Ann Marrie, Scott B Patten, Jamie Greenfield, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Nature Communications|January 10, 2017
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectoriesRenea A Taylor, Michael Fraser, Julie Livingstone, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Brain and Behavior|October 1, 2016
Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosisRuth Ann Marrie, Scott B Patten, Jamie Greenfield, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Nature Communications|January 10, 2017
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectoriesRenea A Taylor, Michael Fraser, Julie Livingstone, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Pageof 8